GNSC-001 gene therapy w/ a recombinant adeno-assoc. viral vector expressing IL-1Ra, to block IL-1. GNSC-001 now in a phase Ib, 50 pt, 10 center USA trial to assess its efficacy in Knee OA. Given as single injx in the affected joint; results in late 2024 https://t.co/jW9FHlGyC2 https://t.co/Dbv15Flqlv